A digital pharmacy founder joins TelyRx’s board as another director steps down
TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF) appointed Benjamin Atkins to its Board of Directors, replacing Andrew Brandt. Atkins brings 25 years of healthcare and real estate experience. The company aims to scale and move towards profitability, according to management.
How this was made
The 30-second read
Why it matters
Board change is a standard corporate governance update with minimal price effect.
Market read
Limited relevance; primarily of interest to existing shareholders and sector watchers.
What to watch
Potential future partnerships leveraging Atkins' real‑estate network.
Background
TelyRx is a technology‑enabled digital pharmacy platform operating in 49 U.S. states.
Market effects
None significant for digital pharmacy sector.
Limited to Canadian market where TELY is listed.
Low
Counterpoint
Board refresh could signal upcoming strategic initiatives, but no concrete evidence yet.
Key entities
- personBenjamin Atkins
Founder and major shareholder joining the board.
- personAndrew Brandt
Departing board member.



